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Background: Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta2 agonist
[LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance
treatments for chronic obstructive pulmonary disease (COPD). This 12-week, multicentre, double-blind, parallel-group,
double-dummy study compared the efficacy and safety of these treatments in symptomatic patients with
moderate-to-severe COPD with no exacerbations in the year prior to enrolment.
Methods: Patients (n = 717) were randomised 1:1 to once-daily UMEC/VI 62.5/25 mcg or twice-daily FP/SAL 500/50 mcg.
Endpoints included 0–24 h weighted mean (wm) forced expiratory volume in 1 s (FEV1) (Day 84; primary), trough FEV1
(Day 85; secondary), other lung function endpoints, symptoms, quality of life (QoL) and safety.
Results: Improvements with UMEC/VI versus FP/SAL were 0.080 L (95 % confidence interval: 0.046–0.113; wmFEV1) and
0.090 L (0.055–0.125; trough FEV1) (both p < 0.001). UMEC/VI statistically significantly improved all other lung function
measures versus FP/SAL. Both treatments demonstrated a clinically meaningful improvement in symptoms (Transition
Dyspnoea Index ≥1 unit) and QoL (St George’s Respiratory Questionnaire Total score ≥4 unit decrease from baseline)
over 12 weeks. The incidence of adverse events was 28 % (UMEC/VI) and 29 % (FP/SAL); nasopharyngitis and headache
were most common.
Conclusions: Once-daily UMEC/VI 62.5/25 mcg over 12 weeks resulted in significant and sustained improvements in
lung function versus twice-daily FP/SAL 500/50 mcg in patients with moderate-to-severe COPD and with no
exacerbations in the year prior to enrolment.
Trial Registration: NCT01822899 Registration date: March 28, 2013Background
For the treatment of chronic obstructive pulmonary dis-
ease (COPD), Global Initiative for Chronic Obstructive
Lung Disease™ (GOLD) [1] recommends a management
strategy based on assessment of the level of symptoms
and degree of risk. There are four categories, with cat-
egories C and D including patients defined as higher risk
than those in categories A and B, on the basis of severe
airflow obstruction (i.e., forced expiratory volume in 1 s
[FEV1] <50 % predicted) and/or a history of ≥2* Correspondence: dsingh@meu.org.uk
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Long-acting bronchodilators are the mainstay of
COPD treatment as they improve lung function, and re-
duce symptoms and exacerbations [1]. Inhaled cortico-
steroids (ICS) are used to reduce exacerbations in
patients with COPD with moderate-to-very severe air-
flow limitation, and there is good evidence for the effi-
cacy of combination ICS/long-acting beta2 agonist
(LABA) treatments in patients with a history of exacer-
bations (i.e., GOLD C and D patients) [1]. However, ICS
are often prescribed to patients without a history of ex-
acerbations and the evidence for efficacy in theses distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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antagonist (LAMA)/LABA therapies offer an alternative
treatment option that may have a better benefit-risk pro-
file in these patients. LAMA/LABA combination treat-
ments are a recognised treatment option for GOLD B, C
or D patients [1]; these treatments maximise lung func-
tion improvements by using two bronchodilators with
different mechanisms of action to provide additive clin-
ical benefits [3].
The LAMA/LABA combination umeclidinium (UMEC)/
vilanterol (VI), delivered via a single inhaler, is approved in
the European Union, United States and several other
countries as a once-daily maintenance treatment for
COPD [4, 5]. Studies in patients with COPD have
shown that UMEC/VI is well tolerated and significantly
improves lung function and symptoms versus placebo
[6, 7] and versus long-acting bronchodilator monother-
apy [6–8]. However, an important clinical question is
how the efficacy of UMEC/VI compares with that of
ICS/LABA combinations, which are often used in
symptomatic patients with COPD who do not have a
history of exacerbations (i.e., GOLD B and a subset of
GOLD D patients).
The primary objective of this study was to compare the
efficacy and safety of once-daily UMEC/VI (62.5/25 mcg)
with twice-daily fluticasone propionate/salmeterol
(FP/SAL) (500/50 mcg) over 12 weeks in patients with
COPD with dyspnoea and without exacerbations in
the year prior to enrolment. FP/SAL is an established
ICS/LABA therapy in COPD [9], and we hypothesised
that UMEC/VI would be a more effective treatment in
this particular group of patients. Preliminary results
have been presented in abstract form [10].Methods
Patients
The inclusion criteria were: male or female patients
≥40 years old; an established COPD clinical history [1]; a
post-salbutamol FEV1/forced vital capacity (FVC) ratio
<0.70 and a post-salbutamol FEV1 of ≥30 % and ≤70 %
of predicted normal values; a dyspnoea score of ≥2
(modified Medical Research Council [mMRC] Dyspnoea
Scale); current or former (stopped smoking for ≥6 months)
cigarette smokers with a history of cigarette smoking
of ≥10 pack-years. Key exclusion criteria were: asthma/
other respiratory disorders; hospitalisation for pneu-
monia within 12 weeks of screening; a documented
history of ≥1 COPD exacerbation requiring oral corti-
costeroids, antibiotics and/or hospitalisation in the
12 months preceding screening.
All patients provided written, informed consent prior to
conducting any study-specific procedures. This study was
approved by local ethics committees (Additional file 1)and performed in accordance with the Declaration of
Helsinki [11] and Good Clinical Practice guidelines [12].
Study design, randomisation and treatment
This study (Additional file 2) was a phase IIIb, multicentre,
randomised, double-blind, double-dummy, parallel-group
trial (GSK study number DB2116134; www.clinicaltrials.-
gov registration number NCT01822899) conducted in 69
centres in eight countries (Czech Republic, Denmark,
Germany, Hungary, The Netherlands, Poland, Russian
Federation and Spain) between 2 April and 7 October
2013.
A validated computer system (RandAll; GSK, Brentford,
UK) was used to generate a central randomisation sched-
ule. Patients were randomised, using a Registration And
Medication Ordering System (RAMOS; GSK, Brentford,
UK), 1:1 to receive either UMEC/VI or FP/SAL. Patients
and study personnel were blinded to the study medication.
After screening, eligible patients had a 7–14-day run-
in period, in which as-needed salbutamol, mucolytics
and as-needed oxygen therapy (≤12 h/day) were the only
permitted COPD treatments, for assessment of baseline
salbutamol use and disease stability. Following random-
isation, patients received either UMEC/VI 62.5/25 mcg
(delivered doses 55/22 mcg) via the ELLIPTA®1 dry pow-
der inhaler (DPI) once daily (morning) and placebo via
the DISKUS®2 inhaler (twice daily, morning and evening
approximately 12 h apart) or FP/SAL 500/50 mcg via
the DISKUS inhaler twice daily and placebo via the
ELLIPTA DPI (once daily in the morning) for 12 weeks.
There were further study visits at Weeks 4, 8 and 12
(end of treatment), and a 7 ± 2 day follow-up safety as-
sessment. Patients were permitted to use salbutamol for
as-needed symptom relief throughout the study, as long
as it was withheld in the 4 h prior to spirometry testing.
Further details of restricted and permitted concomitant
COPD medications are provided in the Additional file 3.
Treatment compliance was assessed by reviewing the in-
haler dose counters at each study visit.
Outcome assessments
Efficacy (lung function) assessments
Spirometry was conducted at each visit. Baseline spir-
ometry assessments were recorded prior to randomisa-
tion, during the same study visit. The primary endpoint
was change from baseline in weighted mean (wm)
FEV1 over 0–24 h on Day 84, calculated from pre-dose
FEV1 and post-dose FEV1 evaluations at 5 and 15 min
and 1, 3, 6, 9, 12 (pre-evening dose), 13, 15, 18, 23 and
24 h after the morning dose. The secondary endpoint
was change from baseline in trough FEV1 on Day 85
(i.e., the mean of the FEV1 values recorded 23 h and
24 h after morning dosing on Day 84). Other lung
function endpoints included (change from baseline
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on Days 1 and 84; time to onset (an increase of ≥0.100 L
above baseline in FEV1 during 0–6 h post-dose on Day 1);
proportion of patients achieving an increase in FEV1 ≥
12 % and ≥0.200 L above baseline at any time during
0–6 h post-dose on Day 1; wmFVC 0–24 h post-dose
on Day 84; trough FVC on Day 85; and wmFVC 0–6 h
post-dose on Days 1 and 84. The proportion of patients
achieving an increase in FEV1 ≥ 0.100 L above baseline
on Day 1 at 5 and 15 min, and 1, 3 and 6 h post-dose
was evaluated in a post hoc analysis.
Symptomatic endpoints and health outcomes
Patients completed daily diaries, including rescue medi-
cation use (puffs/day, percentage of rescue-free days
were calculated). Dyspnoea was assessed using the
Baseline Dyspnoea Index (BDI) focal score at baseline,
and the Transition Dyspnoea Index (TDI) focal score
on Days 28, 56 and 84. Quality of life was assessed
using the St George’s Respiratory Questionnaire for pa-
tients with COPD (SGRQ-C) at baseline and on Days
28 and 84. Health outcome assessments were evaluated
using the EuroQol-5D (EQ-5D) questionnaire at ran-
domisation and on Day 84. The COPD Assessment
Test (CAT) was used to assess COPD-related health
status at baseline and on Day 84.
Safety evaluations
Safety and tolerability included monitoring adverse
events (AEs) throughout the study. AEs were coded
using the Medical Dictionary for Regulatory Activities.
COPD exacerbations were recorded. Vital signs were
evaluated on Days 1 and 84.
Statistical analyses
The sample size calculation was based on a two-sided
5 % significance level and an estimated residual standard
deviation of 0.220 L for wmFEV1 based on a mixed
model for repeated measures (MMRM) analyses of pre-
vious studies in patients with COPD [6–8, 13]. Two
hundred and eighty-four patients/group would have
90 % power to detect a 0.060 L treatment difference in
0–24 h wmFEV1. Assuming a 20 % drop-out rate, ap-
proximately 710 patients (355/group) were to be
randomised.
All analyses were conducted on the intent-to-treat popu-
lation (all randomised patients who took at least one dose
of study medication). To account for multiplicity across
endpoints, a step-down, closed-testing procedure was
used. If the primary endpoint was statistically significant at
the 5 % level, then the secondary endpoint was evaluated.
If the latter was also statistically significant (5 % level) then
inferences at the 5 % significance level would be made for
all other comparisons.An analysis of covariance (ANCOVA) model (covariates:
baseline FEV1, smoking status and treatment) was used to
analyse the 0–24 h wmFEV1 on Day 84. Trough FEV1 on
Day 85 was analysed using MMRM analysis with covar-
iates of baseline FEV1, smoking status, day, treatment,
day by baseline interaction and day by treatment inter-
action, where day is nominal. The primary and second-
ary endpoints were also descriptively analysed by using
the FEV1 % predicted to categorise patients as GOLD B
(FEV1 ≥ 50 % predicted) or GOLD D (FEV1 < 50 % pre-




Of 1009 patients enrolled, 870 were screened, 717 were
randomised (Fig. 1), and 674 completed the study
(UMEC/VI: 334; FP/SAL: 340). The most common rea-
sons for withdrawal are shown in Fig. 1.
At baseline, patient demographics and characteristics
were similar between groups (Table 1) and 55 % and
45 % of patients overall were categorised as GOLD B
and D, respectively. COPD medication taken pre-study
is summarised in the Additional file 3.
Treatment compliance was approximately 100 % in
both treatment groups, and is summarised in the
Additional file 3.
Efficacy
Primary and secondary endpoints
On Day 84, UMEC/VI caused a significantly greater im-
provement of 0.080 L (95 % confidence interval [CI]:
0.046–0.113; p < 0.001) in the least squares (LS) mean
change from baseline in 0–24 h wmFEV1 (primary end-
point) versus FP/SAL (Table 2). The increased effect of
UMEC/VI compared with FP/SAL was also demon-
strated in the 0–24 h serial FEV1 measurements on Day
84 (Fig. 2).
UMEC/VI statistically significantly improved the LS
mean change from baseline in trough FEV1 on Day 85
(secondary endpoint) by 0.090 L (95 % CI: 0.055–0.125;
p < 0.001) versus FP/SAL (Table 2, Fig. 3). Similar im-
provements were also seen on Days 28, 56 and 84
(Fig. 3).
Raw mean change from baseline for the primary and
secondary endpoints was numerically greater in patients
receiving UMEC/VI compared with FP/SAL in both
GOLD B and GOLD D patients, although no statistical
analysis was performed (Table 3). Relative improvements
in mean change from baseline with UMEC/VI versus
FP/SAL were similar for GOLD B and GOLD D patients
for both the primary (0.085 L vs. 0.081 L) and secondary
(0.092 L vs. 0.094 L) endpoints. For both UMEC/VI and
FP/SAL, the raw mean change from baseline for the
Fig. 1 Flow diagram for disposition of patients (CONSORT). Abbreviations: ITT, intent-to-treat; FP/SAL, fluticasone propionate/salmeterol;
UMEC, umeclidinium; VI, vilanterol. aOne patient was randomised in error; this patient was a run-in failure
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in GOLD B compared with GOLD D patients.
Other lung function endpoints
For peak FEV1 over 0–6 h post-dose, statistically signifi-
cantly greater improvements in LS mean change from
baseline were seen with UMEC/VI versus FP/SAL on
Days 1 (p = 0.003) and 84 (p < 0.001) (Table 2). Median
time to onset on Day 1 (increase in FEV1 ≥ 0.100 L
above baseline) was significantly (p = 0.002) shorter with
UMEC/VI compared with FP/SAL (Table 2). The pro-
portion of patients achieving this increase in FEV1 on
Day 1 was significantly greater (p < 0.05) with UMEC/VI
versus FP/SAL at 5 min (Table 2), 15 min, 1, 3 and 6 h
post-dose (Additional file 4). Patients treated with
UMEC/VI had statistically significantly greater odds
than patients treated with FP/SAL of achieving an in-
crease from baseline in FEV1 ≥ 12 % and ≥0.200 L at
any time during 0–6 h post-dose on Day 1 (p = 0.011),
and in trough FEV1 ≥ 0.100 L on Day 85 (p < 0.001;
Additional file 5), versus not achieving these increases.
UMEC/VI also significantly improved FVC end-
points (change from baseline in: wm 0–24 h FVC on
Day 84, trough FVC on Day 85, and wm 0–6 h FVCon Days 1 and 84) compared with FP/SAL (all p < 0.001)
(Additional file 6).Symptomatic endpoints and health outcomes
No differences in rescue salbutamol use, mean TDI
focal score, or SGRQ Total scores were seen between
the UMEC/VI and FP/SAL groups at any time point
(Table 4). UMEC/VI and FP/SAL resulted in clinically
meaningful improvements in mean TDI scores (≥1 unit
focal score) at all time points and in SGRQ Total
scores (≥4 unit decrease from baseline) at all time
points (except on Day 28 in the UMEC/VI group,
where a 3.83-unit decrease was observed) (Table 4).
The mean change from baseline on Day 84 for EQ-5D
utility scores and CAT scores were similar for both
treatments (Table 4).
Safety assessments
There were no unexpected safety findings with either
treatment, and no marked differences were seen in the
AE profiles between groups (Table 5). The incidence of
cardiac AEs (2 % UMEC/VI; <1 % FP/SAL) and pneu-
monia (0 % UMEC/VI; <1 % FP/SAL) was very low in
Table 1 Baseline patient demographics, lung function and clinical characteristics (ITT population)
UMEC/VI 62.5/25 mcg (N = 358) FP/SAL 500/50 mcg (N = 358) Total (N = 716)
Age, mean ± SD, years 61.8 ± 7.94 61.4 ± 8.06 61.6 ± 8.00
Sex: male, n (%) 261 (73) 254 (71) 515 (72)
BMI, mean ± SD (range), kg/m2 27.69 ± 5.085 27.26 ± 5.018 27.47 ± 5.052
(16.9–45.8) (15.6–44.4) (15.6–45.8)
Race, n (%)
White 358 (100) 358 (100) 716 (100)
Smoking history and status
Current smoker, n (%) 204 (57) 217 (61) 421 (59)
Years smoked, mean ± SD (range) 37.8 ± 10.15 37.7 ± 10.27 37.8 ± 10.20
(7–67) (10–70) (7–70)
No. cigarettes/day, mean ± SD (range) 21.6 ± 8.18 20.8 ± 7.72 21.2 ± 7.96
(5–60) (7–80) (5–80)
Smoking pack years, mean ± SD (range) 40.7 ± 19.26 39.4 ± 19.09 40.1 ± 19.17
(10–125) (10–140) (10–140)
COPD history
Duration of COPD, n (%), years
< 1 10 (3) 15 (4) 25 (3)
≥ 1 to <5 141 (39) 140 (39) 281 (39)
≥ 5 to <10 128 (36) 122 (34) 250 (35)
≥ 10 79 (22) 81 (23) 160 (22)
COPD type, n (%)a
Chronic bronchitis 279 (78) 287 (80) 566 (79)
Emphysema 189 (53) 180 (50) 369 (52)
Screening lung function, mean (SD)
Pre-salbutamol FEV1, L 1.423 (0.4573) 1.457 (0.4555) 1.440 (0.4564)
Post-salbutamol FEV1, L 1.550 (0.4488) 1.595 (0.4614) 1.572 (0.4554)
Pre-bronchodilator FEV1/FVC 47.7 (10.70) 48.2 (10.08) 47.9 (10.39)
Post-salbutamol FEV1/FVC 49.0 (10.69) 49.8 (10.19) 49.4 (10.45)
Post-salbutamol percent predicted FEV1, (%) 50.2 (10.85) 51.1 (10.50) 50.6 (10.68)
Percent reversibility to salbutamol, (%) 10.7 (12.64) 10.9 (12.63) 10.8 (12.63)
Reversibility to salbutamol, L 0.127 (0.159) 0.138 (0.154) 0.133 (0.157)
Reversible to salbutamol, n (%) 100 (28) 108 (30) 208 (29)
GOLD stage (percent predicted FEV1), n (%)
Stage B 193 (54) 201 (56) 394 (55)
Stage D 165 (46) 157 (44) 322 (45)
mMRC dyspnoea scale, mean (SD) 2.2 (0.41) 2.2 (0.42) 2.2 (0.41)
Rescue salbutamol use
Puffs per day 2.9 (3.30)b 2.4 (2.38) -
Rescue-free days (%) 24.4 (35.01)b 28.3 (37.40) -
BDI focal score on Day 1 6.2 (1.78) 6.4 (1.58)c -
SGRQ Total score, mean (SD) 46.57 (16.523)d 44.02 (15.756)b -
EQ-5D utility score, mean (SD) 0.70 (0.213) 0.75 (0.191) -
CAT score, mean (SD) 18.48 (6.698) 17.20 (7.031) -
BDI baseline Dyspnoea Index, BMI body mass index, CAT COPD Assessment Test, COPD chronic obstructive pulmonary disease, EQ-5D EuroQol-5D questionnaire,
FP/SAL fluticasone propionate/salmeterol, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GOLD Global initiative for chronic Obstructive Lung
Disease, ITT intent-to-treat, mMRC modified Medical Research Council, SD standard deviation, SGRQ St. George’s Respiratory Questionnaire, UMEC umeclidinium,
VI vilanterol
aPatients could select chronic bronchitis, emphysema or both; bn = 354; cn = 356; dn = 353
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Table 2 Results from the analyses of the primary, secondary and selected other endpoints (ITT population)
Endpoint UMEC/VI 62.5/25 mcg (N = 358) FP/SAL 500/50 mcg (N = 358)
Primary endpoint
wm 0–24 h FEV1 on Day 84, L
n 332 337
LS mean (SE) 1.618 (0.0122) 1.539 (0.0121)
LS mean (SE) change from baseline 0.166 (0.0122) 0.087 (0.0121)
Treatment difference (95 % CI) 0.080 (0.046–0.113)
p < 0.001
Secondary endpoint
Trough FEV1 on Day 85, L
n 344 353
na 333 338
LS mean (SE) 1.600 (0.0126) 1.511 (0.0125)
LS mean (SE) change from baseline 0.151 (0.0126) 0.062 (0.0125)
Treatment difference (95 % CI) 0.090 (0.055–0.125)
p < 0.001
Other endpoints (selected)




LS mean (SE) 1.712 (0.0083) 1.678 (0.0083)
LS mean (SE) change from baseline 0.266 (0.0083) 0.231 (0.0083)





LS mean (SE) 1.773 (0.0131) 1.676 (0.0130)
LS mean (SE) change from baseline 0.327 (0.0131) 0.229 (0.0130)
Treatment difference (95 % CI) 0.097 (0.061–0.134)
p < 0.001
Time to onset on Day 1
(increase in FEV1 ≥ 0.100 L above baseline)
n 358 358
Median time to onset, min 17 60
Hazard ratio (95 % CI) 1.3 (1.1–1.5)
p = 0.002
Analysis of the primary endpoint was performed using ANCOVA with covariates of baseline FEV1, smoking status and treatment. Analysis of the secondary
endpoint was by MMRM analysis including covariates of baseline FEV1, smoking status, day, treatment, day by baseline interaction and day by treatment
interaction, where day is nominal
CI confidence interval, FEV1 forced expiratory volume in 1 s, FP/SAL fluticasone propionate/salmeterol, ITT intent-to-treat, LS least squares, MRMM mixed-effect
model repeated measure model, SE, standard error, UMEC umeclidinium, VI vilanterol, wm weighted mean
aNumber of patients with analysable data at the current time point
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three treated with FP/SAL experienced COPD exacerba-
tions. Further safety results are provided in the
Additional file 3.Discussion
Once-daily UMEC/VI (62.5/25 mcg) for 12 weeks sig-
nificantly improved all lung function endpoints com-
pared with twice-daily FP/SAL (500/50 mcg) in patients
Fig. 2 Change from baseline in FEV1 (L) over 0–24 h on Day 84 (ITT population). Data are least squares mean (95 % CI) change from baseline.
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 s; ITT, intent-to-treat; LS, least squares; FP/SAL, fluticasone propionate/
salmeterol; UMEC, umeclidinium; VI, vilanterol
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not report an exacerbation in the year prior to enrol-
ment. This study extends current understanding of the
benefits of LAMA/LABA compared with ICS/LABA
combination treatment regimens by comparing these
treatments in GOLD B and a subgroup of GOLD DFig. 3 Change from baseline in trough FEV1 (L) (ITT population). Data are leas
FEV1 (L) at Days 28, 56, 84 and 85. Abbreviations: CI, confidence interval; FEV1,
FP/SAL, fluticasone propionate/salmeterol; UMEC, umeclidinium; VI, vilanterolpatients without a history of exacerbations in the year
prior to enrolment.
In this study, patients with COPD with mMRC score ≥2
and without a history of frequent exacerbations were cate-
gorised as either GOLD B (55 %) or D (45 %) on the basis
of lung function, according to GOLD [1]. Consistent witht squares mean (95 % CI) differences of change from baseline in trough
forced expiratory volume in 1 s; ITT, intent-to-treat; LS, least squares;
Table 3 0–24 h wmFEV1 and trough FEV1 by GOLD subgroup (ITT population)
Endpoint UMEC/VI 62.5/25 mcg (N = 358) FP/SAL 500/50 mcg (N = 358)
0–24 h wmFEV1 on Day 84, L, change from baseline
GOLD Ba,b
n 184 189
mean (SD) 0.181 (0.2476) 0.096 (0.2230)
GOLD Db,c
n 148 148
mean (SD) 0.152 (0.2111) 0.071 (0.2038)
Trough FEV1 on Day 85, L, change from baseline
GOLD Ba,b
n 185 189
mean (SD) 0.162 (0.2661) 0.070 (0.2340)
GOLD Db,c
n 148 149
mean (SD) 0.143 (0.2067) 0.049 (0.2160)
Descriptive analyses of change from baseline in 0–24 h wmFEV1 on Day 84 and in trough FEV1 on Day 85 by GOLD subgroup
FEV1 forced expiratory volume in 1 s, FP/SAL fluticasone propionate/salmeterol, GOLD Global Initiative for Chronic Obstructive Lung Disease™, ITT intent-to-treat,
SD standard deviation, UMEC umeclidinium, VI vilanterol, wm weighted mean
aFEV1 ≥ 50 % to <80 % predicted;
bAll but three patients fulfilled the exclusion criterion regarding no exacerbations in the past year—no further details of
exacerbation history were collected; cFEV1 ≥ 30 % to <50 % predicted
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creased effectiveness of inhaled treatments in patients
with COPD with worse lung function [14, 15], in a post
hoc analysis the effectiveness of both treatments on the
primary and secondary endpoints was observed to be nu-
merically greater in GOLD B patients. However, the rela-
tive effectiveness of UMEC/VI and FP/SAL was similar in
both GOLD categories.
A 6-week study in patients with moderate COPD dem-
onstrated that the LAMA tiotropium (18 mcg once daily)
in combination with the LABA formoterol (12 mcg twice
daily), delivered via separate inhalers, significantly im-
proved lung function compared with twice-daily FP/SAL
(500/50 mcg) [16]. The ILLUMINATE study also
demonstrated significant lung function improvements
with once-daily QVA149 (glycopyrronium [a LAMA]/
indacaterol [a LABA] 50/110 mcg) versus twice-daily
FP/SAL (500/50 mcg) in patients with moderate-to-
severe COPD without exacerbations in the previous
year [17]. ILLUMINATE and our study demonstrate
the potential clinical benefits of inhaled LAMA/LABA
fixed-dose combination therapy in patients with
COPD without frequent exacerbations. A key differ-
ence between ILLUMINATE and the present study
was the higher proportion of patients with severe air-
flow obstruction (18 % vs. 45 %, respectively) in our
study. Furthermore, we strictly defined patients as
having increased symptoms using the mMRC Dys-
pnoea Scale as recommended by GOLD [14], and con-
sequently the present study contains a significant
proportion of GOLD D patients.Both UMEC/VI and FP/SAL had a positive impact on
symptomatic endpoints and health outcomes in our
study. However, in contrast to the significantly greater
lung function improvements seen with UMEC/VI versus
FP/SAL, no treatment differences were seen for these
endpoints. These findings are unexpected as improving
lung function often has beneficial effects on such
patient-reported outcomes in patients with COPD [18].
The lack of patient-reported health outcome benefits
with UMEC/VI versus FP/SAL might suggest that
current tools for measuring patient-reported outcomes
are not sensitive enough within this sample size to de-
tect differences between two active treatments. Another
possible explanation is that 12 weeks is too short a
duration to detect differences in patient-reported
outcomes between treatments, and results from the
26-week ILLUMINATE trial [17] support this hypothesis.
While a numerical imbalance in COPD exacerbations
was observed between treatment groups (8 [2 %] patients
in UMEC/VI and 3 [<1 %] patients in FP/SAL), this was a
small difference in a population with a very low exacerba-
tion rate overall. Longer studies of UMEC/VI versus
FP/SAL in a population with greater exacerbation risk are
needed to clarify treatment differences on exacerbation
rate between UMEC/VI and FP/SAL.
Overall, there were no new safety concerns with
UMEC/VI or FP/SAL and both treatments were well tol-
erated in our study, although the duration of treatment
was relatively short (12 weeks). The tolerability profile
with UMEC/VI in this study, particularly the very low
incidence of cardiovascular effects, is similar to that
Table 4 Results for symptomatic endpoints and health outcome measures (ITT population)
Endpoint UMEC/VI 62.5/25 mcg (N = 358) FP/SAL 500/50 mcg (N = 358)
Rescue salbutamol use
Mean number of puffs/day, weeks 1–12
n 334 349
LS mean (SE) 1.3 (0.08) 1.4 (0.08)
LS mean (SE) change from baseline −1.3 (0.08) −1.2 (0.08)
Treatment difference (95 % CI) −0.1 (−0.3–0.1)
p = 0.559
Percent rescue-free days during 12 weeks, change from baseline
n 334 349





LS mean (SE) 1.7 (0.13) 1.6 (0.13)




LS mean (SE) 2.0 (0.12) 1.7 (0.12)




LS mean (SE) 2.0 (0.14) 2.1 (0.13)
Treatment difference (95 % CI) −0.1 (−0.4–0.3)
p = 0.702




LS mean (SE) 41.25 (0.552) 40.03 (0.544)
LS mean change (SE) −3.83 (0.552) −5.05 (0.544)




LS mean (SE) 39.98 (0.626) 39.44 (0.619)
LS mean change (SE) −5.10 (0.626) −5.64 (0.619)
Treatment difference (95 % CI) 0.53 (−1.20–2.26)
p = 0.545
EQ-5D utility score on Day 84, change from baseline
n 335 341
Mean (SD) 0.03 (0.189) 0.03 (0.203)
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Table 4 Results for symptomatic endpoints and health outcome measures (ITT population) (Continued)
CAT score on Day 84, change from baseline
n 335 341
Mean (SD) −2.21 (6.054) −2.35 (6.432)
CAT COPD Assessment Test, CI confidence interval, EQ-5D EuroQoL-5D, FP/SAL fluticasone propionate/salmeterol, ITT intent-to-treat, LS least squares, SE standard
error, SD standard deviation, SGRQ St George’s Respiratory Questionnaire, TDI Transition Dyspnea Index, UMEC umeclidinium, VI vilanterol
aNumber of patients with analysis data for one or more time points
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tients with COPD at the clinical dosing regimen (once-
daily 62.5/25 mcg for 24 weeks) [7, 8]. Similarly, the
FP/SAL tolerability data in our study are similar to those
reported in previous studies [19–21].
A key strength of our study was the direct compari-
son of the approved UMEC/VI regimen with a com-
monly used ICS-based COPD treatment in patients
specifically identified as GOLD B or D. Moreover, the
study recruited approximately equal proportions of pa-
tients categorised as GOLD B or D. Other strengths in-
clude the large sample size, very high compliance with
the study medications, and application of statistical
hierarchy methodology to avoid multiple comparisons
and multiplicity issues. Potential limitations of this





Leading to permanent discontinuation or withdrawal 6 (2)




AEs of special interest, n (%)
Cardiac ischaemiaa 3 (<
Cardiac arrhythmias 3 (<
Pneumonia 0
LRTI (excluding pneumonia) 1 (<
AEs occurring in ≥3 % patients in any treatment group, n (%)
Headache 33 (9
Nasopharyngitis 10 (3
Back pain 7 (2)
Dysphonia 2 (<
COPD exacerbations, n (%) 8 (2)
Summary of incidence of on-treatment AEs, serious AEs, AEs of special interest, mo
AE adverse event, COPD chronic obstructive pulmonary disease, ITT intent-to-treat,
UMEC umeclidinium, VI, vilanterol
aAll anginaGOLD II and III patients, so the potential benefits of
UMEC/VI compared with FP/SAL are unknown in very
severe COPD, and that the study was insufficiently long
to detect treatment differences in side effects.
Conclusion
Once-daily UMEC/VI 62.5/25 mcg over 12 weeks signifi-
cantly improved lung function in symptomatic patients
with moderate-to-severe COPD with no exacerbations in
the year prior to enrolment versus twice-daily FP/SAL
500/50 mcg. ICS/LABA combinations are often prescribed
to the type of patients enrolled in this study (GOLD B and
GOLD D patients without frequent exacerbations). How-
ever, our findings indicate that the corticosteroid-sparing
dual bronchodilator UMEC/VI may offer a better treat-
ment option in these patients.exacerbation (ITT population)
















st frequent AEs and COPD exacerbation
LRTI lower respiratory tract infection, FP/SAL salmeterol/fluticasone propionate,
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1ELLIPTA® is a trade mark of the GSK group of
companies.
2DISKUS® is a trade mark of the GSK group of
companies.
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